A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

NCT06337032 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: F/TAF (High Dose Tablet)
DRUG: F/TAF (Low Dose Tablet)
DRUG: F/TAF (Lowest Dose Tablet)
DRUG: F/TAF (High Dose TOS)
DRUG: F/TAF (Low Dose TOS)
DRUG: F/TAF (Lowest Dose TOS)
DRUG: E/C/F/TAF
DRUG: E/C/F/TAF (Low Dose)
DRUG: Cobicistat (High Dose)
DRUG: Cobicistat (Low Dose)
DRUG: Cobicistat (TOS)
DRUG: B/F/TAF (High Dose)
DRUG: B/F/TAF (Low Dose)
DRUG: B/F/TAF (High Dose TOS)
DRUG: B/F/TAF (Low Dose TOS)
DRUG: B/F/TAF (Lowest Dose TOS)
DRUG: 3rd ARV Agent
DRUG: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
DRUG: ATV
DRUG: DRV

Sponsor

Gilead Sciences